Core Viewpoint - ADC Therapeutics has amended its royalty purchase agreement with HealthCare Royalty, enhancing strategic flexibility and reducing financial obligations related to potential change of control events [2][3]. Financial Terms - The change of control payment has been reduced from $750 million to $150 million until the end of 2027, and to $200 million thereafter [2][6]. - HealthCare Royalty will continue to receive royalties on sales by any acquirer until the original royalty cap is reached [2]. - HealthCare Royalty has been granted warrants to purchase approximately 9.8 million common shares at an exercise price of $3.81 per share, exercisable until December 31, 2030, with a lock-up period until the end of 2027 [2][3]. Product Overview - ZYNLONTA is a CD19-directed antibody drug conjugate that targets and kills tumor cells by delivering a potent payload that binds to DNA [5]. - The FDA and EMA have approved ZYNLONTA for treating adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy [7][9]. Market Potential - ADC Therapeutics anticipates significant growth for ZYNLONTA starting in 2027, with potential peak revenue in the U.S. estimated to reach between $600 million to $1 billion annually, assuming compendia inclusion and regulatory approval [3]. - The confidence in ZYNLONTA's potential is bolstered by existing and upcoming clinical data, particularly in diffuse large B-cell lymphoma and other indolent lymphomas [3]. Company Background - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates, focused on transforming treatment for patients through its portfolio, including ZYNLONTA [8]. - The company is headquartered in Lausanne, Switzerland, with operations in New Jersey, and is committed to driving innovation in ADC development [10].

Financial Data and Key Metrics Changes - Total revenue for 2025 grew by 38% to $1.4 billion, with royalty revenue increasing by 52% to $868 million, reflecting strong performance from ENHANZE-enabled products [9][17] - Net income for the full year was $316.9 million, down from $444.1 million in 2024, impacted by a $285 million acquired IP R&D expense [19] - Adjusted EBITDA was $657.6 million, compared to $632.2 million in 2024, indicating operational strength despite the IP charge [19] Business Line Data and Key Metrics Changes - DARZALEX Subcutaneous generated $483 million in royalty revenue, a 29% year-over-year growth, with total sales reaching $14.4 billion [10] - PHESGO's royalty revenue increased by 51% to $105.6 million, with total sales growing 48% year-over-year to approximately $3 billion [11] - VYVGART and VYVGART Hytrulo saw a 444% year-over-year growth in royalty revenues to $157.2 million, with total sales reaching $4.15 billion [12] Market Data and Key Metrics Changes - ENHANZE now has 10 global blockbuster opportunities, with significant approvals in the U.S., Japan, and China for various products [8][16] - The subcutaneous formulations of Ocrevus, Opdivo, RYBREVANT, and Tecentriq represent a combined market opportunity of approximately $30 billion by 2028 [13] Company Strategy and Development Direction - The company aims to expand its ENHANZE pipeline, projecting 6 new programs to enter phase one in 2026, bringing the total development portfolio to 15 products [24] - The strategy includes pursuing additional licensing agreements and evaluating new drug delivery technologies to enhance long-term revenue streams [27][28] - Hypercon technology is expected to meet the demand for lower volume, auto-injector-ready therapies, with projections of approximately $1 billion in royalty revenue within five years of the first launches [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the company, emphasizing the durability of royalty revenue and the potential for exceptional value creation [23] - The company anticipates continued strong growth driven by existing products and new collaborations, with a focus on expanding into new therapeutic areas [25][36] Other Important Information - The company completed acquisitions of Elektrofi and Surf Bio, enhancing its drug delivery capabilities and extending IP into the mid-2040s [6][27] - The balance sheet was strengthened with the issuance of convertible notes and an upsized revolving credit facility, reducing near-term refinancing risk [21] Q&A Session Summary Question: Regarding the DARZALEX collaboration with J&J - Management expects to enter discussions with J&J to extend the agreement closer to its expiration in 2032, emphasizing the importance of the partnership [42] Question: On the ADC strategy and regulatory paths - The regulatory pathway for converting ADCs from IV to subcutaneous is expected to follow traditional PK non-inferiority studies, with additional trials for unapproved products [50] Question: Update on Hypercon products and clinical testing - Two Hypercon products are on track for phase 1 clinical testing in 2026, with completion of clinical scale-up batches and IND filings underway [66] Question: Potential incremental royalty opportunities from Merus's petosemtamab - Management highlighted the potential for expanded indications and the importance of subcutaneous formulations in enhancing patient treatment experiences [58]

Financial Data and Key Metrics Changes - Total revenue grew 38% to $1.4 billion, with royalty revenue increasing 52% to $868 million for the full year 2025 [9][17][19] - Net income for the full year was $316.9 million, compared to $444.1 million in 2024, while adjusted EBITDA was $657.6 million, up from $632.2 million in 2024 [19][20] - GAAP diluted EPS was $2.50, down from $3.43 in 2024, while non-GAAP diluted EPS was $4.15, compared to $4.23 in 2024 [19][20] Business Line Data and Key Metrics Changes - DARZALEX Subcutaneous generated $483 million in royalty revenue, a 29% year-over-year growth, with total sales reaching $14.4 billion [10][19] - Phesgo's royalty revenue increased 51% year-over-year to $105.6 million, with total sales growing 48% to approximately $3 billion [11][19] - VYVGART and VYVGART Hytrulo saw a 444% year-over-year growth in royalty revenues to $157.2 million, with total sales reaching $4.15 billion [12][19] Market Data and Key Metrics Changes - ENHANZE-enabled products now include 10 global blockbuster opportunities, with significant approvals in multiple markets including the U.S., Japan, and China [8][16] - The subcutaneous formulations of Ocrevus, Opdivo, RYBREVANT, and Tecentriq represent a combined market opportunity of approximately $30 billion by 2028 [13][16] Company Strategy and Development Direction - The company aims to expand its ENHANZE portfolio with six new programs entering phase I in 2026, bringing the total development portfolio to 15 products [24][35] - Hypercon technology is expected to meet the demand for lower volume, auto-injector-ready therapies, with projections of approximately $1 billion in royalty revenue within five years of the first launches [26][27] - The company plans to pursue strategic acquisitions to enhance its drug delivery portfolio while maintaining financial discipline [27][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the company, highlighting multiple revenue drivers and the durability of royalty revenue [23][39] - The company anticipates continued strong growth from existing products and new launches, with a focus on expanding into new therapeutic areas [24][35] Other Important Information - The company completed acquisitions of Elektrofi and Surf Bio, enhancing its drug delivery capabilities with long-duration IP [6][27] - The company expects to maintain a strong balance sheet and reduce net debt to below 1x by the end of 2026 [21][22] Q&A Session Summary Question: Regarding the mechanics of DARZALEX collaboration with J&J - Management expects to enter discussions with J&J to extend the agreement closer to its expiration in 2032, emphasizing the importance of the partnership [42][43] Question: On the ADC strategy and regulatory paths - Management indicated that the regulatory pathway for converting IV to subcutaneous delivery would likely follow traditional PK non-inferiority studies [49][50] Question: Update on Hypercon products and clinical testing - Management confirmed that two Hypercon products are on track for phase I clinical testing in 2026, with completion of clinical scale-up batches underway [63][64] Question: Expectations for new partnerships in auto-injectors - Management anticipates progress with high-volume auto-injectors and expects to see interest from both current and new partners [75][76]

Core Insights - ADC Therapeutics announced updated data from the LOTIS-7 Phase 1b trial, showing ZYNLONTA® combined with glofitamab (COLUMVI®) achieved an 89.8% overall response rate (ORR) and a 77.6% complete response (CR) rate in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) [1][2] Company Overview - ADC Therapeutics is a global leader in antibody drug conjugates (ADCs), focusing on innovative treatments for patients with hematological malignancies [2] - The company is headquartered in Lausanne, Switzerland, with operations in London and New Jersey [2] Clinical Trial Highlights - The LOTIS-7 trial is designed to evaluate the safety and efficacy of ZYNLONTA in combination with various agents, including glofitamab, in patients with B-cell non-Hodgkin lymphoma [1] - As of November 17, 2025, 49 patients were efficacy-evaluable, with a minimum of 6 months follow-up [1] - The trial aims to complete enrollment of approximately 100 patients by the first half of 2026, with full data expected to be shared at a medical meeting and submitted for publication by the end of 2026 [1] Efficacy Data - The best overall response rate (ORR) was 89.8%, with 44 out of 49 patients responding [1] - The complete response (CR) rate was 77.6%, with 33 of the 38 patients who achieved CR remaining in that state at the data cutoff [1] - In the subgroup of 24 relapsed patients, the ORR was 100% and the CR rate was 91.7% [1] - Among 25 primary refractory patients, the ORR was 80% and the CR rate was 64% [1] Safety Profile - The combination treatment was generally well tolerated, with a manageable safety profile [1] - Grade 3 or higher treatment-emergent adverse events (TEAEs) included neutropenia (32.7%), GGT increased (16.3%), and anemia (10.2%) [1] - Cytokine release syndrome (CRS) occurred in 36.7% of patients, with varying severity across dose levels [1] Future Plans - The company plans to assess regulatory and compendia strategies for ZYNLONTA and its combinations [1] - ADC Therapeutics is also advancing a next-generation PSMA-targeting ADC, leveraging its expertise in ADC development [2]

Core Insights - The novel spliceosome targeting payload, PH1, shows potential in inducing cancer cell cytotoxicity and activating anti-tumor immunity through various mechanisms [1][3] - The combination of Trastuzumab-PH1 ADC with anti-PD1 therapy significantly outperforms Kadcyla® with anti-PD1 in achieving complete tumor regressions (74% vs. 42%, p<0.05) [1][12] - Akari Therapeutics is advancing its lead ADC candidate, AKTX-101, which targets the Trop2 receptor and utilizes the PH1 payload, aiming to enter clinical trials soon [7][9] Company Overview - Akari Therapeutics is focused on developing next-generation spliceosome payload antibody drug conjugates (ADCs) [9] - The company’s innovative ADC platform allows for the generation and optimization of ADC candidates tailored to specific targets [9] - The PH1 payload is designed to disrupt RNA splicing in cancer cells, leading to cancer cell death and immune activation [9] Mechanism of Action - Trastuzumab-PH1 induces RNA mis-splicing, resulting in increased neoantigen generation and a subsequent rise in anti-cancer immune cells within the tumor microenvironment [4][12] - The combination therapy enhances immune responses, including the polarization of macrophages, increase in neutrophils, and expansion of B cell clones producing IgM antibodies [3][12] - The synergy between Trastuzumab PH1 and anti-PD1 therapy is attributed to their complementary effects on the immune system, particularly the expansion of gamma-delta T cell clones [3][12] Market Potential - The immuno-oncology therapeutic class is currently valued at approximately $50 billion per year, with the potential for significant growth through innovative therapies like those developed by Akari [1][4] - The unique results from the Trastuzumab-PH1 and anti-PD1 combination therapy could establish a new standard of care in cancer treatment, improving patient outcomes [6][12] Upcoming Events - Akari Therapeutics will host a live webcast on November 18, 2025, to discuss the presented data, providing insights for investors and analysts [1][8]

Core Insights - ADC Therapeutics is advancing its clinical programs for ZYNLONTA, with updated data from LOTIS-7 expected by the end of 2025 and topline results from LOTIS-5 anticipated in the first half of 2026 [1][5][2] Financial Results - For Q3 2025, net product revenues were $15.8 million, a decrease from $18.0 million in Q3 2024. Year-to-date revenues were $51.2 million compared to $52.9 million for the same period in 2024 [4][19] - Research and Development (R&D) expenses for Q3 2025 were $26.8 million, down from $32.5 million in Q3 2024. Year-to-date R&D expenses increased to $85.8 million from $82.5 million in 2024 [4][19] - Selling and Marketing (S&M) expenses remained stable at $10.7 million for Q3 2025, with a slight decrease in year-to-date expenses to $31.4 million from $32.8 million in 2024 [4][19] - General and Administrative (G&A) expenses decreased to $8.3 million for Q3 2025 from $10.0 million in Q3 2024, and year-to-date G&A expenses were $27.1 million compared to $32.3 million in 2024 [4][19] - The net loss for Q3 2025 was $41.0 million, or $0.30 per share, an improvement from a net loss of $44.0 million, or $0.42 per share, in Q3 2024. Year-to-date net loss was $136.2 million, compared to $127.1 million in 2024 [4][19] Operational Updates - The company completed a $60 million PIPE financing, with net proceeds of approximately $57.6 million expected to fund the commercial expansion of ZYNLONTA [2][5] - Updated data from the Phase 2 investigator-initiated trial of ZYNLONTA in r/r follicular lymphoma showed an overall response rate of 98.2% and a complete response rate of 83.6% [5][4] - IND-enabling activities for a PSMA-targeting ADC are ongoing, with completion expected by the end of 2025 [5][4] Future Outlook - Multiple clinical catalysts are anticipated across LOTIS-7, LOTIS-5, and ongoing Phase 2 IITs, with the first data readout expected before the end of 2025 [2][5] - The company plans to engage with the FDA once sufficient data from LOTIS-7 is available, with potential regulatory submissions and approvals expected in 2027 [5][4]

Core Insights - AbbVie is experiencing significant growth in its immunology drugs, particularly Skyrizi and Rinvoq, which are offsetting declines from Humira and its aesthetics division [2][4][5] - The company reported third-quarter sales of $15.78 billion, exceeding expectations, with a notable operational growth of 8.4% [4] - AbbVie raised its full-year earnings guidance, now expecting adjusted earnings of $10.61 to $10.65 per share, which is above analyst projections [7] Financial Performance - Skyrizi generated $4.71 billion in sales, a 47% increase, while Rinvoq sales reached $2.18 billion, growing 35% [2] - Overall sales for AbbVie grew more than 9% year-over-year, surpassing the expected $15.59 billion [4] - Adjusted earnings per share were reported at $1.86, despite a 38% decline due to a tax charge, still beating projections of $1.77 [4] Product Performance - Humira sales fell to $993 million, facing competition from lower-cost biosimilars [5] - Sales from Botox and Juvederm declined nearly 4% to $1.19 billion, missing expectations [5] - The neuroscience segment, which includes Botox, saw a 20% increase in sales to $2.84 billion, exceeding forecasts [6] Future Outlook - Analysts are optimistic about the long-term growth potential from AbbVie's Parkinson's disease franchise and late-stage antibody drug conjugates [8] - AbbVie stock is currently finding support near its 21-day moving average, indicating potential stability [8]

Core Points - Akari Therapeutics has entered into a definitive agreement for the issuance and sale of 3,125,000 American Depositary Shares (ADSs) at a price of $0.80 per ADS in a registered direct offering [1] - The gross proceeds from the offering are expected to be approximately $2.5 million, which will be used for working capital, general corporate purposes, and continued research and development [4] Offering Details - Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering [2] - The company will also issue unregistered Series E and Series F Warrants to purchase up to 3,125,000 ADSs at an exercise price of $0.98 per share [3] - The offering is expected to close on or about October 16, 2025, subject to customary closing conditions [3] Research and Development Focus - The funds from the offering will be used to generate differentiated data on the novel ADC payload, which targets cancer cells and aims to highlight its unique action against cancer [4] - Akari's lead candidate, AKTX-101, utilizes a novel spliceosome modulator payload designed to disrupt RNA splicing within cancer cells, showing significant activity in preclinical studies [8][9] Company Overview - Akari Therapeutics is focused on developing next-generation spliceosome payload antibody drug conjugates (ADCs) [8] - The company aims to advance its lead asset, AKTX-101, and other undisclosed targets with its novel payload [9]

Core Insights - ADC Therapeutics announced updated Phase 2 data for ZYNLONTA® showing an overall response rate (ORR) of 85% and a complete response (CR) rate of 69% in patients with relapsed/refractory marginal zone lymphoma (r/r MZL) [1][2] - The treatment was well tolerated, with safety profiles consistent with previous data [2][6] - The study is ongoing, with plans to expand enrollment to 50 patients across multiple sites [3][4] Study Details - The Phase 2 trial is a single-arm, open-label study led by Dr. Izidore S. Lossos at Sylvester Comprehensive Cancer Center [1][3] - As of February 10, 2025, 27 adult patients were enrolled, with 26 evaluable for response [2] - Among patients assessed for response, a CR rate of 61.5% was observed in high-risk POD24 patients [6] Efficacy and Safety - The longest duration of CR was 27 months from the start of treatment, with a progression-free survival (PFS) rate of 92.9% at 12 months [6] - Adverse events were consistent with the known safety profile of ZYNLONTA, with most being grade 1 or 2 [6] - Serious adverse events included neutropenia and RSV lung infection, with some patients requiring dose reductions [6] Regulatory and Future Plans - ZYNLONTA has received accelerated approval from the FDA and conditional approval from the European Medicines Agency for treating r/r large B-cell lymphoma [7][10] - The company plans to pursue regulatory pathways based on the ongoing trial results [4] - ZYNLONTA is also being evaluated in combination studies for other B-cell malignancies [8][10] Company Overview - ADC Therapeutics is a biotechnology company focused on developing targeted antibody drug conjugates (ADCs) for cancer treatment [9][10] - The company is based in Lausanne, Switzerland, with operations in London and New Jersey [11]

Core Insights - ADC Therapeutics announced promising results from the LOTIS-7 Phase 1b clinical trial, showing an overall response rate (ORR) of 95.5% and a complete response (CR) rate of 90.9% among 22 evaluable patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) [1][4] - The combination of ZYNLONTA and glofitamab demonstrated a manageable safety profile, with adverse events consistent with known profiles of the individual agents [2][4] - Updated data will be presented at the European Hematology Association 2025 Congress (EHA2025) and the International Conference on Malignant Lymphoma (ICML) [1][5] Efficacy and Safety Data - In the efficacy evaluable population, the ORR was 95.5% (21 out of 22 patients), and the CR rate was 90.9% (20 out of 22 patients) [4] - Among 31 patients treated, the most common Grade ≥3 treatment-emergent adverse event (TEAE) was neutropenia at 32.3% [4] - Other notable Grade 3/4 TEAEs included generalized edema, pericardial effusion, photosensitivity reaction, rash, sepsis, and pneumonia, each at 3.2% [4] Presentation Details - The LOTIS-7 data will be presented in a poster session at EHA2025 on June 14, 2025, with the presenting author being Juan Pablo Alderuccio, MD [3][5] - An oral encore presentation will take place at ICML on June 20, 2025, also featuring Juan Pablo Alderuccio as the presenting author [5] Study Overview - LOTIS-7 is a Phase 1b global multicenter study evaluating ZYNLONTA in combination with various agents, including glofitamab, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma [6] - The study includes a dose escalation phase and a dose expansion phase, with primary endpoints focusing on safety and tolerability [6] About ZYNLONTA - ZYNLONTA is a CD19-directed antibody drug conjugate (ADC) approved for treating adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy [9][12] - The drug works by binding to CD19-expressing cells and delivering a potent payload that leads to tumor cell death [8]